|
1
|
GBD 2013 Mortality and Causes of Death
Collaborators: Global, regional, and national age-sex specific
all-cause and cause-specific mortality for 240 causes of death,
1990-2013: A systematic analysis for the global burden of disease
study 2013. Lancet. 385:117–171. 2015.
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
|
|
3
|
Jiang MC, Ni JJ, Cui WY, Wang BY and Zhuo
W: Emerging roles of lncRNA in cancer and therapeutic
opportunities. Am J Cancer Res. 9:1354–1366. 2019.
|
|
4
|
Ivanov KI, Samuilova OV and Zamyatnin AA
Jr: The emerging roles of long noncoding RNAs in lymphatic vascular
development and disease. CellCell Mol Life Sci. 80:1972023.
|
|
5
|
Statello L, Guo CJ, Chen LL and Huarte M:
Gene regulation by long non-coding RNAs and its biological
functions. Nat Rev Mol Cell Biol. 22:96–118. 2021.
|
|
6
|
Yang X, Liu M, Li M, Zhang S, Hiju H, Sun
J, Mao Z, Zheng M and Feng B: Epigenetic modulations of noncoding
RNA: A novel dimension of cancer biology. Mol Cancer.
19:642020.
|
|
7
|
Mattick JS, Amaral PP, Carninci P,
Carpenter S, Chang HY, Chen LL, Chen R, Dean C, Dinger ME,
Fitzgerald KA, et al: Long non-coding RNAs: Definitions, functions,
challenges and recommendations. Nat Rev Mol Cell Biol. 24:430–447.
2023.
|
|
8
|
Mo Y, Adu-Amankwaah J, Qin W, Gao T, Hou
X, Fan M, Liao X, Jia L, Zhao J, Yuan J and Tan R: Unlocking the
predictive potential of long non-coding RNAs: A machine learning
approach for precise cancer patient prognosis. Ann Med.
55:22797482023.
|
|
9
|
Loewer S, Cabili MN, Guttman M, Loh YH,
Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, et al:
Large intergenic non-coding RNA-RoR modulates reprogramming of
human induced pluripotent stem cells. Nat Genet. 42:1113–1117.
2010.
|
|
10
|
Fernandes JCR, Acuña SM, Aoki JI,
Floeter-Winter LM and Muxel SM: Long non-coding RNAs in the
regulation of gene expression: Physiology and disease. Noncoding
RNA. 5:172019.
|
|
11
|
Yang Z, Jiang S, Shang J, Jiang Y, Dai Y,
Xu B, Yu Y, Liang Z and Yang Y: LncRNA: Shedding light on
mechanisms and opportunities in fibrosis and aging. Ageing Res Rev.
52:17–31. 2019.
|
|
12
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017.
|
|
13
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021.
|
|
14
|
Zhang C, Zhou Y, Zhang B, Sheng Z, Sun N,
Yuan B and Wu X: Identification of lncRNA, miRNA and mRNA
expression profiles and ceRNA Networks in small cell lung cancer.
BMC Genomics. 24:2172023.
|
|
15
|
Li G, Kryczek I, Nam J, Li X, Li S, Li J,
Wei S, Grove S, Vatan L, Zhou J, et al: LIMIT is an immunogenic
lncRNA in cancer immunity and immunotherapy. Nat Cell Biol.
23:526–537. 2021.
|
|
16
|
Wang P, Wang Z, Zhu L, Sun Y, Castellano
L, Stebbing J, Yu Z and Peng L: A pyroptosis-related lncRNA
signature in bladder cancer. Cancer Med. 12:6348–6364. 2023.
|
|
17
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.
|
|
18
|
Howlader N, Noone AM, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER cancer statistics review, 1975-2016. National Cancer
Institute; Bethesda, MD: 2019
|
|
19
|
Tannenbaum SL, Koru-Sengul T, Zhao W, Miao
F and Byrne MM: Survival disparities in non-small cell lung cancer
by race, ethnicity, and socioeconomic status. Cancer J. 20:237–245.
2014.
|
|
20
|
Birring SS and Peake MD: Symptoms and the
early diagnosis of lung cancer. Thorax. 60:268–269. 2005.
|
|
21
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020.
|
|
22
|
Nevedomskaya E, Baumgart SJ and Haendler
B: Recent advances in prostate cancer treatment and drug discovery.
Int J Mol Sci. 19:13592018.
|
|
23
|
Ciccarese C, Nobili E, Grilli D, Casolari
L, Rihawi K, Gelsomino F, Tortora G and Massari F: The safety and
efficacy of enzalutamide in the treatment of advanced prostate
cancer. Expert Rev Anticancer Ther. 16:681–696. 2016.
|
|
24
|
Kastenberg D, Bertiger G and Brogadir S:
Bowel preparation quality scales for colonoscopy. World J
Gastroenterol. 24:2833–2843. 2018.
|
|
25
|
Kong X, Duan Y, Sang Y, Li Y, Zhang H,
Liang Y, Liu Y, Zhang N and Yang Q: LncRNA-CDC6 promotes breast
cancer progression and function as ceRNA to target CDC6 by sponging
microRNA-215. J Cell Physiol. 234:9105–9117. 2019.
|
|
26
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003.
|
|
27
|
Ghafouri-Fard S, Esmaeili M and Taheri M:
H19 lncRNA: Roles in tumorigenesis. Biomed Pharmacother.
123:1097742020.
|
|
28
|
Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang
B, Dong Q, Jiang N, Flores-Morales A, Chang C and Niu Y: LncRNA
PCAT1 activates AKT and NF-κB signaling in castration-resistant
prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
Nucleic Acids Res. 47:4211–4225. 2019.
|
|
29
|
Zong S, Dai W, Guo X and Wang K:
LncRNA-SNHG1 promotes macrophage M2-like polarization and
contributes to breast cancer growth and metastasis. Aging (Albany
NY). 13:23169–23181. 2021.
|
|
30
|
Yue X, Wu WY, Dong M and Guo M: LncRNA
MALAT1 promotes breast cancer progression and doxorubicin
resistance via regulating miR-570-3p. Biomed J. 44(6 Suppl 2):
S296–S304. 2021.
|
|
31
|
Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y,
Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated
with clinical outcome in breast cancer patients. Med Oncol.
31:2592014.
|
|
32
|
Mantovani A, Sica A and Locati M: New
vistas on macrophage differentiation and activation. Eur J Immunol.
37:14–16. 2007.
|
|
33
|
DeNardo DG, Barreto JB, Andreu P, Vasquez
L, Tawfik D, Kolhatkar N and Coussens LM: CD4(+) T cells regulate
pulmonary metastasis of mammary carcinomas by enhancing protumor
properties of macrophages. Cancer Cell. 16:91–102. 2009.
|
|
34
|
Shiao SL, Ruffell B, DeNardo DG, Faddegon
BA, Park CC and Coussens LM: TH2-polarized CD4(+) T cells and
macrophages limit efficacy of radiotherapy. Cancer Immunol Res.
3:518–525. 2015.
|
|
35
|
Li GH, Yu JH, Yang B, Gong FC and Zhang
KW: LncRNA LOXL1-AS1 inhibited cell proliferation, migration and
invasion as well as induced apoptosis in breast cancer via
regulating miR-143-3p. Eur Rev Med Pharmacol Sci. 23:10400–10409.
2019.
|
|
36
|
Li D, Hu J, Song H, Xu H, Wu C, Zhao B,
Xie D, Wu T, Zhao J and Fang L: miR-143-3p targeting LIM domain
kinase 1 suppresses the progression of triple-negative breast
cancer cells. Am J Transl Res. 9:2276–2285. 2017.
|
|
37
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017.
|
|
38
|
Zhang Q, Han Z, Zhu Y, Chen J and Li W:
The role and specific mechanism of OCT4 in cancer stem cells: A
review. Int J Stem Cells. 13:312–325. 2020.
|
|
39
|
Jen J, Tang YA, Lu YH, Lin CC, Lai WW and
Wang YC: Oct4 transcriptionally regulates the expression of long
non-coding RNAs NEAT1 and MALAT1 to promote lung cancer
progression. Mol Cancer. 16:1042017.
|
|
40
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
|
|
41
|
Faubert B, Li KY, Cai L, Hensley CT, Kim
J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al:
Lactate metabolism in human lung tumors. Cell. 171:358–371.e9.
2017.
|
|
42
|
Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L,
Liu J and Huang G: LINC01123, a c-Myc-activated long non-coding
RNA, promotes proliferation and aerobic glycolysis of non-small
cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol.
12:912019.
|
|
43
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012.
|
|
44
|
Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu
X, Lai W, Liu Y, Wang X, Xiao D, et al: EGLN1/c-Myc induced
lymphoid-specific helicase inhibits ferroptosis through lipid
metabolic gene expression changes. Theranostics. 7:3293–3305.
2017.
|
|
45
|
Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu
N, Shi Y, Chen L, Xiao D, Yu F, et al: Long noncoding RNA LINC00336
inhibits ferroptosis in lung cancer by functioning as a competing
endogenous RNA. Cell Death Differ. 26:2329–2343. 2019.
|
|
46
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285.
2017.
|
|
47
|
Hayano M, Yang WS, Corn CK, Pagano NC and
Stockwell BR: Loss of cysteinyl-tRNA synthetase (CARS) induces the
transsulfuration pathway and inhibits ferroptosis induced by
cystine deprivation. Cell Death Differ. 23:270–278. 2016.
|
|
48
|
Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu
J, He Y, Wei Z and Zhang C: Long non-coding RNA H19 promotes
colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin
Cancer Res. 39:1412020.
|
|
49
|
Wu Y, Yang X, Chen Z, Tian L, Jiang G,
Chen F, Li J, An P, Lu L, Luo N, et al: m6A-induced
lncRNA RP11 triggers the dissemination of colorectal cancer cells
via upregulation of Zeb1. Mol Cancer. 18:872019.
|
|
50
|
Dong T, Yang D, Li R, Zhang L, Zhao H,
Shen Y, Zhang X, Kong B and Wang L: PGRN promotes migration and
invasion of epithelial ovarian cancer cells through an epithelial
mesenchymal transition program and the activation of cancer
associated fibroblasts. Exp Mol Pathol. 100:17–25. 2016.
|
|
51
|
Ding D, Li C, Zhao T, Li D, Yang L and
Zhang B: LncRNA H19/miR-29b-3p/PGRN axis promoted
epithelial-mesenchymal transition of colorectal cancer cells by
acting on Wnt signaling. Mol Cells. 41:423–435. 2018.
|
|
52
|
Zhang M, Weng W, Zhang Q, Wu Y, Ni S, Tan
C, Xu M, Sun H, Liu C, Wei P and Du X: The lncRNA NEAT1 activates
Wnt/β-catenin signaling and promotes colorectal cancer progression
via interacting with DDX5. J Hematol Oncol. 11:1132018.
|
|
53
|
Romano S, D'Angelillo A, Staibano S,
Ilardi G and Romano MF: FK506-binding protein 51 is a possible
novel tumoral marker. Cell Death Dis. 1:e552010.
|
|
54
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009.
|
|
55
|
He JH, Zhang JZ, Han ZP, Wang L, Lv YB and
Li YG: Reciprocal regulation of PCGEM1 and miR-145 promote
proliferation of LNCaP prostate cancer cells. J Exp Clin Cancer
Res. 33:722014.
|
|
56
|
Pomerantz MM, Li F, Takeda DY, Lenci R,
Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, et
al: The androgen receptor cistrome is extensively reprogrammed in
human prostate tumorigenesis. Nat Genet. 47:1346–1351. 2015.
|
|
57
|
Zhang Y, Huang YX, Wang DL, Yang B, Yan
HY, Lin LH, Li Y, Chen J, Xie LM, Huang YS, et al: LncRNA DSCAM-AS1
interacts with YBX1 to promote cancer progression by forming a
positive feedback loop that activates FOXA1 transcription network.
Theranostics. 10:10823–10837. 2020.
|
|
58
|
Lang C, Dai Y, Wu Z, Yang Q, He S, Zhang
X, Guo W, Lai Y, Du H, Wang H, et al: SMAD3/SP1 complex-mediated
constitutive active loop between lncRNA PCAT7 and TGF-β signaling
promotes prostate cancer bone metastasis. Mol Oncol. 14:808–828.
2020.
|
|
59
|
Lang C, Yin C, Lin K, Li Y, Yang Q, Wu Z,
Du H, Ren D, Dai Y and Peng X: m6A modification of
lncRNA PCAT6 promotes bone metastasis in prostate cancer through
IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med.
11:e4262021.
|
|
60
|
Burfeind P, Chernicky CL, Rininsland F and
Ilan J and Ilan J: Antisense RNA to the type I insulin-like growth
factor receptor suppresses tumor growth and prevents invasion by
rat prostate cancer cells in vivo. Proc Natl Acad Sci USA.
93:7263–7268. 1996.
|
|
61
|
Wen S, Wei Y, Zen C, Xiong W, Niu Y and
Zhao Y: Long non-coding RNA NEAT1 promotes bone metastasis of
prostate cancer through N6-methyladenosine. Mol Cancer.
19:1712020.
|
|
62
|
Baniwal SK, Khalid O, Gabet Y, Shah RR,
Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA and Frenkel B:
Runx2 transcriptome of prostate cancer cells: Insights into
invasiveness and bone metastasis. Mol Cancer. 9:2582010.
|
|
63
|
Akech J, Wixted JJ, Bedard K, van der Deen
M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR,
Altieri DC, et al: Runx2 association with progression of prostate
cancer in patients: Mechanisms mediating bone osteolysis and
osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010.
|
|
64
|
Zhao JC and Yu J, Runkle C, Wu L, Hu M, Wu
D, Liu JS, Wang Q, Qin ZS and Yu J: Cooperation between Polycomb
and androgen receptor during oncogenic transformation. Genome Res.
22:322–331. 2012.
|
|
65
|
Hu CY, Chen J, Qin XH, You P, Ma J, Zhang
J, Zhang H and Xu JD: Long non-coding RNA NORAD promotes the
prostate cancer cell extracellular vesicle release via
microRNA-541-3p-regulated PKM2 to induce bone metastasis of
prostate cancer. J Exp Clin Cancer Res. 40:982021.
|
|
66
|
Mo C, Huang B, Zhuang J, Jiang S, Guo S
and Mao X: LncRNA nuclear-enriched abundant transcript 1 shuttled
by prostate cancer cells-secreted exosomes initiates osteoblastic
phenotypes in the bone metastatic microenvironment via
miR-205-5p/runt-related transcription factor 2/splicing factor
proline- and glutamine-rich/polypyrimidine tract-binding protein 2
axis. Clin Transl Med. 11:e4932021.
|
|
67
|
Xie Y, Rong L, He M, Jiang Y, Li H, Mai L
and Song F: LncRNA SNHG3 promotes gastric cancer cell proliferation
and metastasis by regulating the miR-139-5p/MYB axis. Aging (Albany
NY). 13:25138–25152. 2021.
|
|
68
|
Jia Y, Ding X, Zhou L, Zhang L and Yang X:
Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains
tumorigenesis in bladder cancer by targeting PRC1. Oncogene.
40:246–261. 2021.
|
|
69
|
Hou J, Zhuo H, Chen X, Cheng J, Zheng W,
Zhong M and Cai J: MiR-139-5p negatively regulates PMP22 to repress
cell proliferation by targeting the NF-κB signaling pathway in
gastric cancer. Int J Biol Sci. 16:1218–1229. 2020.
|
|
70
|
Zhu X, Luo C, Bu F, Lin K and Zhu Z: Long
non-coding RNA RP11-59H7.3 promotes cell proliferation and invasion
metastasis in colorectal cancer by miR-139-5p/NOTCH1 axis. Aging
(Albany NY). 12:11653–11666. 2020.
|
|
71
|
Xie JJ, Jiang YY, Jiang Y, Li CQ, Lim MC,
An O, Mayakonda A, Ding LW, Long L, Sun C, et al:
Super-enhancer-driven long non-coding RNA LINC01503, regulated by
TP63, is over-expressed and oncogenic in squamous cell carcinoma.
Gastroenterology. 154:2137–2151.e1. 2018.
|
|
72
|
Ma Z, Gao X, Shuai Y, Wu X, Yan Y, Xing X
and Ji J: EGR1-mediated linc01503 promotes cell cycle progression
and tumorigenesis in gastric cancer. Cell Prolif.
54:e129222021.
|
|
73
|
Xie C, Guo Y and Lou S: LncRNA ANCR
promotes invasion and migration of gastric cancer by regulating
FoxO1 expression to inhibit macrophage M1 polarization. Dig Dis
Sci. 65:2863–2872. 2020.
|
|
74
|
Chung S, Ranjan R, Lee YG, Park GY,
Karpurapu M, Deng J, Xiao L, Kim JY, Unterman TG and Christman JW:
Distinct role of FoxO1 in M-CSF- and GM-CSF-differentiated
macrophages contributes LPS-mediated IL-10: Implication in
hyperglycemia. J Leukoc Biol. 97:327–339. 2015.
|
|
75
|
Moritoki Y, Zhang W, Tsuneyama K, Yoshida
K, Wakabayashi K, Yang GX, Bowlus C, Ridgway WM, Ueno Y, Ansari AA,
et al: B cells suppress the inflammatory response in a mouse model
of primary biliary cirrhosis. Gastroenterology. 136:1037–1047.
2009.
|
|
76
|
Yang JB, Zhao ZB, Liu QZ, Hu TD, Long J,
Yan K and Lian ZX: FoxO1 is a regulator of MHC-II expression and
anti-tumor effect of tumor-associated macrophages. Oncogene.
37:1192–1204. 2018.
|
|
77
|
Engreitz JM, Pandya-Jones A, McDonel P,
Shishkin A, Sirokman K, Surka C, Kadri S, Xing J, Goren A, Lander
ES, et al: The Xist lncRNA exploits three-dimensional genome
architecture to spread across the X chromosome. Science.
341:12379732013.
|
|
78
|
Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu
C, Ye W, Liao Y, Jia J and Zhang R: Long non-coding RNA XIST
inhibited breast cancer cell growth, migration, and invasion via
miR-155/CDX1 axis. Biochem Biophys Res Commun. 498:1002–1008.
2018.
|
|
79
|
Petrović N, Kolaković A, Stanković A,
Lukić S, Řami A, Ivković M and Mandušić V: MiR-155 expression level
changes might be associated with initial phases of breast cancer
pathogenesis and lymph-node metastasis. Cancer Biomark. 16:385–394.
2016.
|
|
80
|
Qin CX, Yang XQ, Jin GC and Zhan ZY:
LncRNA TSLNC8 inhibits proliferation of breast cancer cell through
the miR-214-3p/FOXP2 axis. Eur Rev Med Pharmacol Sci. 23:8440–8448.
2019.
|
|
81
|
Yang W, Qian Y, Gao K, Zheng W, Wu G, He
Q, Chen Q, Song Y, Wang L, Wang Y, et al: LncRNA BRCAT54 inhibits
the tumorigenesis of non-small cell lung cancer by binding to RPS9
to transcriptionally regulate JAK-STAT and calcium pathway genes.
Carcinogenesis. 42:80–92. 2021.
|
|
82
|
Wan Y, Yao D, Fang F, Wang Y, Wu G and
Qian Y: LncRNA WT1-AS downregulates lncRNA UCA1 to suppress
non-small cell lung cancer and predicts poor survival. BMC Cancer.
21:1042021.
|
|
83
|
Deng X, Xiong W, Jiang X, Zhang S, Li Z,
Zhou Y, Xiang B, Zhou M, Li X, Li G, et al: LncRNA LINC00472
regulates cell stiffness and inhibits the migration and invasion of
lung adenocarcinoma by binding to YBX1. Cell Death Dis.
11:9452020.
|
|
84
|
Gao T, Dai X, Jiang Y, He X, Yuan S and
Zhao P: LncRNA HAND2-AS1 inhibits proliferation and promotes
apoptosis of non-small cell lung cancer cells by inactivating
PI3K/Akt pathway. Biosci Rep. 40:BSR202018702020.
|
|
85
|
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou
A, Liu J, Che L and Li J: Long noncoding RNA GAS5 inhibits
progression of colorectal cancer by interacting with and triggering
YAP phosphorylation and degradation and is negatively regulated by
the m6A reader YTHDF3. Mol Cancer. 18:1432019.
|
|
86
|
Naik R and Galande S: SATB family
chromatin organizers as master regulators of tumor progression.
Oncogene. 38:1989–2004. 2019.
|
|
87
|
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K,
Liu X, Xu T, Sun L, Qin J, et al: LncRNA SATB2-AS1 inhibits tumor
metastasis and affects the tumor immune cell microenvironment in
colorectal cancer by regulating SATB2. Mol Cancer. 18:1352019.
|
|
88
|
Bai J, Xu J, Zhao J and Zhang R: LncRNA
NBR2 suppresses migration and invasion of colorectal cancer cells
by downregulating miRNA-21. Hum Cell. 33:98–103. 2020.
|
|
89
|
Osei GY, Adu-Amankwaah J, Koomson S,
Beletaa S, Ahmad MK, Asiamah EA, Smith-Togobo C and Abdul Razak SR:
Revolutionizing colorectal cancer treatment: Unleashing the
potential of miRNAs in targeting cancer stem cells. Future Oncol.
19:2369–2382. 2023.
|
|
90
|
Osei GY, Adu-Amankwaah J, Koomson S,
Beletaa S, Asiamah EA, Smith-Togobo C and Razak SRA: MicroRNAs and
colorectal cancer: Clinical potential and regulatory networks. Mol
Biol Rep. 50:9575–9585. 2023.
|
|
91
|
Zhou Y, Yang H, Xia W, Cui L, Xu R, Lu H,
Xue D, Tian Z, Ding T, Cao Y, et al: LncRNA MEG3 inhibits the
progression of prostate cancer by facilitating H3K27 trimethylation
of EN2 through binding to EZH2. J Biochem. 167:295–301. 2020.
|
|
92
|
Morgan R: Engrailed: Complexity and
economy of a multi-functional transcription factor. FEBS Lett.
580:2531–2533. 2006.
|
|
93
|
Zhou YJ, Yang HQ, Xia W, Cui L, Xu RF, Lu
H, Xue Z, Zhang B, Tian ZN, Cao YJ, et al: Down-regulation of
miR-605 promotes the proliferation and invasion of prostate cancer
cells by up-regulating EN2. Life Sci. 190:7–14. 2017.
|
|
94
|
Yang Y, Liu PY, Bao W, Chen SJ, Wu FS and
Zhu PY: Hydrogen inhibits endometrial cancer growth via a
ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway. BMC Cancer.
20:282020.
|
|
95
|
Ren N, Jiang T, Wang C, Xie S, Xing Y,
Piao D, Zhang T and Zhu Y: LncRNA ADAMTS9-AS2 inhibits gastric
cancer (GC) development and sensitizes chemoresistant GC cells to
cisplatin by regulating miR-223-3p/NLRP3 axis. Aging (Albany NY).
12:11025–11041. 2020.
|
|
96
|
Yang XZ, Cheng TT, He QJ, Lei ZY, Chi J,
Tang Z, Liao QX, Zhang H, Zeng LS and Cui SZ: LINC01133 as ceRNA
inhibits gastric cancer progression by sponging miR-106a-3p to
regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer.
17:1262018.
|
|
97
|
Zhang M, Yang L, Hou L and Tang X: LncRNA
SNHG1 promotes tumor progression and cisplatin resistance through
epigenetically silencing miR-381 in breast cancer. Bioengineered.
12:9239–9250. 2021.
|
|
98
|
Du C, Wang Y, Zhang Y, Zhang J, Zhang L
and Li J: LncRNA DLX6-AS1 contributes to epithelial-mesenchymal
transition and cisplatin resistance in triple-negative breast
cancer via modulating Mir-199b-5p/paxillin axis. Cell Transplant.
29:9636897209299832020.
|
|
99
|
Liu Y, Li M, Yu H and Piao H: lncRNA CYTOR
promotes tamoxifen resistance in breast cancer cells via sponging
miR-125a-5p. Int J Mol Med. 45:497–509. 2020.
|
|
100
|
Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai
Z, Zhu M, Li Q, Li Y, et al: LncRNA DILA1 inhibits cyclin D1
degradation and contributes to tamoxifen resistance in breast
cancer. Nat Commun. 11:55132020.
|
|
101
|
Yu Q, Li Y, Peng S, Li J and Qin X:
Exosomal-mediated transfer of OIP5-AS1 enhanced cell
chemoresistance to trastuzumab in breast cancer via up-regulating
HMGB3 by sponging miR-381-3p. Open Med (Wars). 16:512–525.
2021.
|
|
102
|
Chen J, Liu A, Wang Z, Wang B, Chai X, Lu
W, Cao T, Li R, Wu M, Lu Z, et al: LINC00173.v1 promotes
angiogenesis and progression of lung squamous cell carcinoma by
sponging miR-511-5p to regulate VEGFA expression. Mol Cancer.
19:982020.
|
|
103
|
Zeng F, Wang Q, Wang S, Liang S, Huang W,
Guo Y, Peng J, Li M, Zhu W and Guo L: Linc00173 promotes
chemoresistance and progression of small cell lung cancer by
sponging miR-218 to regulate Etk expression. Oncogene. 39:293–307.
2020.
|
|
104
|
Hua G, Zeng ZL, Shi YT, Chen W, He LF and
Zhao GF: LncRNA XIST contributes to cisplatin resistance of lung
cancer cells by promoting cellular glycolysis through sponging
miR-101-3p. Pharmacology. 106:498–508. 2021.
|
|
105
|
Xu X, Zhou X, Chen Z, Gao C, Zhao L and
Cui Y: Silencing of lncRNA XIST inhibits non-small cell lung cancer
growth and promotes chemosensitivity to cisplatin. Aging (Albany
NY). 12:4711–4726. 2020.
|
|
106
|
Zhuang ST, Cai YJ, Liu HP, Qin Y and Wen
JF: LncRNA NEAT1/miR-185-5p/IGF2 axis regulates the invasion and
migration of colon cancer. Mol Genet Genomic Med. 8:e11252020.
|
|
107
|
Wang X, Jiang G, Ren W, Wang B, Yang C and
Li M: LncRNA NEAT1 regulates 5-Fu sensitivity, apoptosis and
invasion in colorectal cancer through the MiR-150-5p/CPSF4 axis.
Onco Targets Ther. 13:6373–6383. 2020.
|
|
108
|
Zhu Y, Hu H, Yuan Z, Zhang Q, Xiong H, Hu
Z, Wu H, Huang R, Wang G and Tang Q: LncRNA NEAT1 remodels
chromatin to promote the 5-Fu resistance by maintaining colorectal
cancer stemness. Cell Death Dis. 11:9622020.
|
|
109
|
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu
Y, Feng Y, Liu H, Fei B, Mao Y, et al: LncRNA-UCA1 enhances cell
proliferation and 5-fluorouracil resistance in colorectal cancer by
inhibiting miR-204-5p. Sci Rep. 6:238922016.
|
|
110
|
Chen B, Dragomir MP, Fabris L, Bayraktar
R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, et al:
The long noncoding RNA CCAT2 induces chromosomal instability
through BOP1-AURKB signaling. Gastroenterology. 159:2146–2162.e33.
2020.
|
|
111
|
Ding J, Li J, Wang H, Tian Y, Xie M, He X,
Ji H, Ma Z, Hui B, Wang K and Ji G: Long noncoding RNA CRNDE
promotes colorectal cancer cell proliferation via epigenetically
silencing DUSP5/CDKN1A expression. Cell Death Dis. 8:e29972017.
|
|
112
|
Li P, Zhang X, Wang L, Du L, Yang Y, Liu
T, Li C and Wang C: lncRNA HOTAIR contributes to 5FU resistance
through suppressing miR-218 and activating NF-κB/TS signaling in
colorectal cancer. Mol Ther Nucleic Acids. 8:356–369. 2017.
|
|
113
|
Zhang B, Zhang M, Shen C, Liu G, Zhang F,
Hou J and Yao W: LncRNA PCBP1-AS1-mediated AR/AR-V7
deubiquitination enhances prostate cancer enzalutamide resistance.
Cell Death Dis. 12:8562021.
|
|
114
|
Jiang L, Zhang Y, Su P, Ma Z, Ye X, Kang
W, Liu Y and Yu J: Long non-coding RNA HNF1A-AS1 induces 5-FU
resistance of gastric cancer through miR-30b-5p/EIF5A2 pathway.
Transl Oncol. 18:1013512022.
|
|
115
|
Xin L, Zhou LQ, Liu C, Zeng F, Yuan YW,
Zhou Q, Li SH, Wu Y, Wang JL, Wu DZ and Lu H: Transfer of LncRNA
CRNDE in TAM-derived exosomes is linked with cisplatin resistance
in gastric cancer. EMBO Rep. 22:e521242021.
|
|
116
|
Zhu Y, Zhou B, Hu X, Ying S, Zhou Q, Xu W,
Feng L, Hou T, Wang X, Zhu L and Jin H: LncRNA LINC00942 promotes
chemoresistance in gastric cancer by suppressing MSI2 degradation
to enhance c-Myc mRNA stability. Clin Transl Med. 12:e7032022.
|
|
117
|
Fu T, Ji K, Jin L, Zhang J, Wu X, Ji X,
Fan B, Jia Z, Wang A, Liu J, et al: ASB16-AS1 up-regulated and
phosphorylated TRIM37 to activate NF-κB pathway and promote
proliferation, stemness, and cisplatin resistance of gastric
cancer. Gastric Cancer. 24:45–59. 2021.
|
|
118
|
Zhou J, Lin J, Zhang H, Zhu F and Xie R:
LncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer
progression by upregulating KLF14. Biochem Biophys Res Commun.
503:1848–1853. 2018.
|
|
119
|
Ghildiyal R, Sawant M, Renganathan A,
Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY and Mahajan
NP: Loss of long noncoding RNA NXTAR in prostate cancer augments
androgen receptor expression and enzalutamide resistance. Cancer
Res. 82:155–168. 2022.
|
|
120
|
Li Q, Fu L, Han L, Li S, Zhang Y and Wang
J: Long noncoding RNA GAS5 accelerates cholangiocarcinoma
progression by regulating hsa-miR-1297. Cancer Manag Res.
13:2745–2753. 2021.
|
|
121
|
Sun M, Jin FY, Xia R, Kong R, Li JH, Xu
TP, Liu YW, Zhang EB, Liu XH and De W: Decreased expression of long
noncoding RNA GAS5 indicates a poor prognosis and promotes cell
proliferation in gastric cancer. BMC Cancer. 14:3192014.
|
|
122
|
Cao S, Liu W, Li F, Zhao W and Qin C:
Decreased expression of lncRNA GAS5 predicts a poor prognosis in
cervical cancer. Int J Clin Exp Pathol. 7:6776–6783. 2014.
|
|
123
|
Chang L, Li C, Lan T, Wu L, Yuan Y, Liu Q
and Liu Z: Decreased expression of long non-coding RNA GAS5
indicates a poor prognosis and promotes cell proliferation and
invasion in hepatocellular carcinoma by regulating vimentin. Mol
Med Rep. 13:1541–1550. 2016.
|
|
124
|
Dong Q, Long X, Cheng J, Wang W, Tian Q
and Di W: LncRNA GAS5 suppresses ovarian cancer progression by
targeting the miR-96-5p/PTEN axis. Ann Transl Med. 9:17702021.
|
|
125
|
Wang Y, Zhu P, Luo J, Wang J, Liu Z, Wu W,
Du Y, Ye B, Wang D, He L, et al: LncRNA HAND2-AS1 promotes liver
cancer stem cell self-renewal via BMP signaling. EMBO J.
38:e1011102019.
|
|
126
|
Dong G, Wang X, Jia Y, Jia Y, Zhao W,
Zhang J and Tong Z: HAND2-AS1 works as a ceRNA of miR-3118 to
suppress proliferation and migration in breast cancer by
upregulating PHLPP2. Biomed Res Int. 2020:81245702020.
|
|
127
|
Jiang Z, Li L, Hou Z, Liu W, Wang H, Zhou
T, Li Y and Chen S: LncRNA HAND2-AS1 inhibits 5-fluorouracil
resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
Cell Signal. 66:1094832020.
|
|
128
|
Xu Z, Lv H, Wang Y, Hu C, Chen S, Du Y,
Shi C and Cheng X: HAND2-AS1 inhibits gastric adenocarcinoma cells
proliferation and aerobic glycolysis via miRNAs sponge. Cancer
Manag Res. 12:3053–3068. 2020.
|
|
129
|
Gong J, Fan H, Deng J and Zhang Q: LncRNA
HAND2-AS1 represses cervical cancer progression by interaction with
transcription factor E2F4 at the promoter of C16orf74. J Cell Mol
Med. 24:6015–6027. 2020.
|
|
130
|
Shan L, Liu W and Zhan Y: LncRNA HAND2-AS1
exerts anti-oncogenic effects on bladder cancer via restoration of
RARB as a sponge of microRNA-146. Cancer Cell Int. 21:3612021.
|
|
131
|
Li Y, Wan Q, Wang W, Mai L, Sha L, Mashrah
M, Lin Z and Pan C: LncRNA ADAMTS9-AS2 promotes tongue squamous
cell carcinoma proliferation, migration and EMT via the
miR-600/EZH2 axis. Biomed Pharmacother. 112:1087192019.
|
|
132
|
Luo T, Gao Y, Zhangyuan G, Xu X, Xue C,
Jin L, Zhang W, Zhu C, Sun B and Qin X: lncRNA PCBP1-AS1 aggravates
the progression of hepatocellular carcinoma via regulating
PCBP1/PRL-3/AKT pathway. Cancer Manag Res. 12:5395–5408. 2020.
|
|
133
|
Li L, Peng Q, Gong M, Ling L, Xu Y and Liu
Q: Using lncRNA sequencing to reveal a putative lncRNA-mRNA
correlation network and the potential role of PCBP1-AS1 in the
pathogenesis of cervical cancer. Front Oncol. 11:6347322021.
|
|
134
|
Wang H, Ouyang L and Gao S: Effects of
antisense lncRNA PCBP1-AS1 on biological behaviors of vulvar
squamous carcinoma cells by regulating TRAF5 and NF-κB expression.
Transl Cancer Res. 8:1578–1590. 2019.
|
|
135
|
Zhang D, Zhou H, Liu J and Mao J: Long
noncoding RNA ASB16-AS1 promotes proliferation, migration, and
invasion in glioma cells. Biomed Res Int. 2019:54375312019.
|
|
136
|
Li M, Yin B, Chen M, Peng J, Mu X, Deng Z,
Xiao J, Li W and Fan J: Downregulation of the lncRNA ASB16-AS1
decreases LARP1 expression and promotes clear cell renal cell
carcinoma progression via miR-185-5p/miR-214-3p. Front Oncol.
10:6171052021.
|
|
137
|
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu
XY, Yu ZW, Jia YH, Bai XF, Li L, et al: The lncRNA CRNDE promotes
colorectal cancer cell proliferation and chemoresistance via
miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol
Cancer. 16:92017.
|
|
138
|
Zhu HY, Gao YJ, Wang Y, Liang C, Zhang ZX
and Chen Y: LncRNA CRNDE promotes the progression and angiogenesis
of pancreatic cancer via miR-451a/CDKN2D axis. Transl Oncol.
14:1010882021.
|
|
139
|
Bai X, Wang W, Zhao P, Wen J, Guo X, Shen
T, Shen J and Yang X: LncRNA CRNDE acts as an oncogene in cervical
cancer through sponging miR-183 to regulate CCNB1 expression.
Carcinogenesis. 41:111–121. 2020.
|
|
140
|
Wang Q, Wang LX, Zhang CY, Bai N, Feng C,
Zhang ZM, Wang L and Gao ZZ: LncRNA CRNDE promotes cell
proliferation, migration and invasion of ovarian cancer via
miR-423-5p/FSCN1 axis. Mol Cell Biochem. 477:1477–1488. 2022.
|
|
141
|
Cui WW, Sun YL, Chen C, Feng RR, Xu W,
Meng JJ and Zhang K: LncRNA CRNDE promotes the development of
Wilms' tumor by regulating microRNA-424. Eur Rev Med Pharmacol Sci.
24:1088–1097. 2020.
|
|
142
|
Tang D, Zhao L, Peng C, Ran K, Mu R and Ao
Y: LncRNA CRNDE promotes hepatocellular carcinoma progression by
upregulating SIX1 through modulating miR-337-3p. J Cell Biochem.
120:16128–16142. 2019.
|
|
143
|
Zhu Y, Li B, Xu G, Han C and Xing G:
Knockdown of long noncoding RNA colorectal neoplasia differentially
expressed inhibits hepatocellular carcinoma progression by
mediating the expression of nuclear autoantigenic sperm protein.
Oncol Rep. 46:2522021.
|
|
144
|
Sun H, He L, Ma L, Lu T, Wei J, Xie K and
Wang X: LncRNA CRNDE promotes cell proliferation, invasion and
migration by competitively binding miR-384 in papillary thyroid
cancer. Oncotarget. 8:110552–110565. 2017.
|
|
145
|
Fan YF, Yu ZP and Cui XY: lncRNA
colorectal neoplasia differentially expressed (CRNDE) promotes
proliferation and inhibits apoptosis in non-small cell lung cancer
cells by regulating the miR-641/CDK6 axis. Med Sci Monit.
25:2745–2755. 2019.
|
|
146
|
Fu D, Zang L, Li Z, Fan C, Jiang H and Men
T: Long non-coding RNA CRNDE regulates the growth and migration of
prostate cancer cells by targeting microRNA-146a-5p. Bioengineered.
12:2469–2479. 2021.
|
|
147
|
Ding Q, Mo F, Cai X, Zhang W, Wang J, Yang
S and Liu X: LncRNA CRNDE is activated by SP1 and promotes
osteosarcoma proliferation, invasion, and epithelial-mesenchymal
transition via Wnt/β-catenin signaling pathway. J Cell Biochem.
121:3358–3371. 2020.
|
|
148
|
Hu CE, Du PZ, Zhang HD and Huang GJ: Long
noncoding RNA CRNDE promotes proliferation of gastric cancer cells
by targeting miR-145. Cell Physiol Biochem. 42:13–21. 2017.
|
|
149
|
Huan J, Xing L, Lin Q, Xui H and Qin X:
Long noncoding RNA CRNDE activates Wnt/β-catenin signaling pathway
through acting as a molecular sponge of microRNA-136 in human
breast cancer. Am J Transl Res. 9:1977–1989. 2017.
|
|
150
|
Wang Y, Zhou Q and Ma JJ: High expression
of lnc-CRNDE presents as a biomarker for acute myeloid leukemia and
promotes the malignant progression in acute myeloid leukemia cell
line U937. Eur Rev Med Pharmacol Sci. 22:763–770. 2018.
|
|
151
|
Song H, Han LM, Gao Q and Sun Y: Long
non-coding RNA CRNDE promotes tumor growth in medulloblastoma. Eur
Rev Med Pharmacol Sci. 20:2588–2597. 2016.
|
|
152
|
Xia XL, Xue D, Xiang TH, Xu HY, Song DK,
Cheng PG and Wang JQ: Overexpression of long non-coding RNA CRNDE
facilitates epithelial-mesenchymal transition and correlates with
poor prognosis in intrahepatic cholangiocarcinoma. Oncol Lett.
15:4105–4112. 2018.
|
|
153
|
Wang Y, Wang Y, Li J, Zhang Y, Yin H and
Han B: CRNDE, a long-noncoding RNA, promotes glioma cell growth and
invasion through mTOR signaling. Cancer Lett. 367:122–128.
2015.
|
|
154
|
Zhao Z, Liu M, Long W, Yuan J, Li H, Zhang
C, Tang G, Jiang W, Yuan X, Wu M and Liu Q: Knockdown lncRNA CRNDE
enhances temozolomide chemosensitivity by regulating autophagy in
glioblastoma. Cancer Cell Int. 21:4562021.
|
|
155
|
David A, Zocchi S, Talbot A, Choisy C,
Ohnona A, Lion J, Cuccuini W, Soulier J, Arnulf B, Bories JC, et
al: The long non-coding RNA CRNDE regulates growth of multiple
myeloma cells via an effect on IL6 signalling. Leukemia.
35:1710–1721. 2021.
|
|
156
|
Xu L, Zhang Y, Zhao Z, Chen Z, Wang Z, Xu
S, Zhang X, Liu T and Yu S: The long non-coding RNA CRNDE competed
endogenously with miR-205 to promote proliferation and metastasis
of melanoma cells by targeting CCL18. Cell Cycle. 17:2296–2308.
2018.
|
|
157
|
Shen S, Liu H, Wang Y, Wang J, Ni X, Ai Z,
Pan H, Liu H and Shao Y: Long non-coding RNA CRNDE promotes
gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and
C-IAP1 complexes to activating PI3K-AKT pathway. Oncotarget.
7:72833–72844. 2016.
|
|
158
|
Ni J, Hong J, Li Q, Zeng Q and Xia R: Long
non-coding RNA CRNDE suppressing cell proliferation is regulated by
DNA methylation in chronic lymphocytic leukemia. Leuk Res.
105:1065642021.
|
|
159
|
Yu Y, Lu X, Yang C and Yin F: Long
noncoding RNA LINC00173 contributes to the growth, invasiveness and
chemo-resistance of colorectal cancer through regulating
miR-765/PLP2 axis. Cancer Manag Res. 12:3363–3369. 2020.
|
|
160
|
Zhang J, Zhou M, Zhao X, Wang G and Li J:
Long noncoding RNA LINC00173 is downregulated in cervical cancer
and inhibits cell proliferation and invasion by modulating the
miR-182-5p/FBXW7 axis. Pathol Res Pract. 216:1529942020.
|
|
161
|
Zhang J, Zhu N and Chen X: A novel long
noncoding RNA LINC01133 is upregulated in lung squamous cell cancer
and predicts survival. Tumour Biol. 36:7465–7471. 2015.
|
|
162
|
Feng Y, Qu L, Wang X and Liu C: LINC01133
promotes the progression of cervical cancer by sponging miR-4784 to
up-regulate AHDC1. Cancer Biol Ther. 20:1453–1461. 2019.
|
|
163
|
Liu S and Xi X: LINC01133 contribute to
epithelial ovarian cancer metastasis by regulating miR-495-3p/TPD52
axis. Biochem Biophys Res Commun. 533:1088–1094. 2020.
|
|
164
|
Zhang J, Gao S, Zhang Y, Yi H, Xu M, Xu J,
Liu H, Ding Z, He H, Wang H, et al: MiR-216a-5p inhibits
tumorigenesis in pancreatic cancer by targeting TPT1/mTORC1 and is
mediated by LINC01133. Int J Biol Sci. 16:2612–2627. 2020.
|
|
165
|
Song Z, Zhang X, Lin Y, Wei Y, Liang S and
Dong C: LINC01133 inhibits breast cancer invasion and metastasis by
negatively regulating SOX4 expression through EZH2. J Cell Mol Med.
23:7554–7565. 2019.
|
|
166
|
Kong J, Sun W, Li C, Wan L, Wang S, Wu Y,
Xu E, Zhang H and Lai M: Long non-coding RNA LINC01133 inhibits
epithelial-mesenchymal transition and metastasis in colorectal
cancer by interacting with SRSF6. Cancer Lett. 380:476–484.
2016.
|
|
167
|
Foroughi K, Amini M, Atashi A,
Mahmoodzadeh H, Hamann U and Manoochehri M: Tissue-specific
down-regulation of the long non-coding RNAs PCAT18 and LINC01133 in
gastric cancer development. Int J Mol Sci. 19:38812018.
|
|
168
|
Yang ZY, Yang F, Zhang YL, Liu B, Wang M,
Hong X, Yu Y, Zhou YH and Zeng H: LncRNA-ANCR down-regulation
suppresses invasion and migration of colorectal cancer cells by
regulating EZH2 expression. Cancer Biomark. 18:95–104. 2017.
|
|
169
|
Li Z, Hou P, Fan D, Dong M, Ma M, Li H,
Yao R, Li Y, Wang G, Geng P, et al: The degradation of EZH2
mediated by lncRNA ANCR attenuated the invasion and metastasis of
breast cancer. Cell Death Differ. 24:59–71. 2017.
|
|
170
|
Wang S, Lan F and Xia Y: lncRA ANCR
inhibits non-small cell lung cancer cell migration and invasion by
inactivating TGF-β pathway. Med Sci Monit. 24:6002–6009. 2018.
|
|
171
|
Si Y, Yang Z, Ge Q, Yu L, Yao M, Sun X,
Ren Z and Ding C: Long non-coding RNA Malat1 activated autophagy,
hence promoting cell proliferation and inhibiting apoptosis by
sponging miR-101 in colorectal cancer. Cell Mol Biol Lett.
24:502019.
|
|
172
|
Zheng X, Ren J, Peng B, Ye J, Wu X, Zhao
W, Li Y, Chen R, Gong X, Bai C, et al: MALAT1 overexpression
promotes the growth of colon cancer by repressing β-catenin
degradation. Cell Signal. 73:1096762020.
|
|
173
|
Chen W, Tan X, Yang Q, Fang Z and Xu Y:
MALAT1 enhances gemcitabine resistance in non-small cell lung
cancer cells by directly affecting miR-27a-5p/PBOV1 axis. Cell
Signal. 94:1103262022.
|
|
174
|
Zhang D, Fang C, Li H, Lu C, Huang J, Pan
J, Yang Z, Liang E, Liu Z, Zhou X, et al: Long ncRNA MALAT1
promotes cell proliferation, migration, and invasion in prostate
cancer via sponging miR-145. Transl Androl Urol. 10:2307–2319.
2021.
|
|
175
|
Mao Y, Li W, Weng Y, Hua B, Gu X, Lu C, Xu
B, Xu H and Wang Z: METTL3-mediated m6A modification of
lncRNA MALAT1 facilitates prostate cancer growth by activation of
PI3K/AKT signaling. Cell Transplant. 31:96368972211229972022.
|
|
176
|
Deng QJ, Xie LQ and Li H: Overexpressed
MALAT1 promotes invasion and metastasis of gastric cancer cells via
increasing EGFL7 expression. Life Sci. 157:38–44. 2016.
|
|
177
|
Lu Z, Luo T, Pang T, Du Z, Yin X, Cui H,
Fang G and Xue X: MALAT1 promotes gastric adenocarcinoma through
the MALAT1/miR-181a-5p/AKT3 axis. Open Biol. 9:1900952019.
|
|
178
|
Kwok ZH, Roche V, Chew XH, Fadieieva A and
Tay Y: A non-canonical tumor suppressive role for the long
non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer.
143:668–678. 2018.
|
|
179
|
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang
Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al: Long noncoding RNA
MALAT1 suppresses breast cancer metastasis. Nat Genet.
50:1705–1715. 2018.
|
